Valproate (All indications)

Maternal consequences (as a whole)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12706
R47942		 Alsfouk (Valproate), 2022 Maternal complication (bleeding during pregnancy, gestational hypertension, eclampsia, preeclampsia, gestational diabetes, cervical cerclage, placenta abruption, prolonged labor, pre-mature rupture of membranes, seizure on day of delivery or during delivery, and post-partum hemorrhage) during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: No 2.86 [0.52;15.77] C 5/12   3/15 8 12
ref
S9441
R33150		 Wen (Valproate) (Mixed indications), 2017 Pregnancy and obstetrical complications during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.32 [1.00;1.74] C 76/226   12,176/43,956 12,252 226
ref
Total 2 studies 1.35 [1.03;1.77] 12,260 238
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Alsfouk (Valproate), 2022Alsfouk, 2022 1 2.86[0.52; 15.77]8123%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Wen (Valproate) (Mixed indications), 2017Wen, 2017 2 1.32[1.00; 1.74]12,25222697%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 1.35[1.03; 1.77]12,2602380.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Valproate; 2: Valproate) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.35[1.03; 1.77]12,2602380%NAAlsfouk (Valproate), 2022 Wen (Valproate) (Mixed indications), 2017 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.32[1.00; 1.74]12,252226 -NAWen (Valproate) (Mixed indications), 2017 1 exposed to other treatment, sickexposed to other treatment, sick 2.86[0.52; 15.77]812 -NAAlsfouk (Valproate), 2022 1 Tags Adjustment   - No  - No 1.35[1.03; 1.77]12,2602380%NAAlsfouk (Valproate), 2022 Wen (Valproate) (Mixed indications), 2017 2 All studiesAll studies 1.35[1.03; 1.77]12,2602380%NAAlsfouk (Valproate), 2022 Wen (Valproate) (Mixed indications), 2017 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.32[1.00; 1.74]12,252226 -NAWen (Valproate) (Mixed indications), 2017 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.86[0.52; 15.77]812 -NAAlsfouk (Valproate), 2022 10.510.01.0